Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Dec. 31, 2018
Mar. 31, 2019
Feb. 28, 2018
REVENUES $ 1,852 $ 7,301 $ 2,636
COST OF REVENUES 1,221 4,344 1,644
GROSS PROFIT 631 2,957 992
RESEARCH AND DEVELOPMENT EXPENSES, net 1,431 5,150 766
AMORTIZATION OF INTANGIBLE ASSETS 179 517 436
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 1,984 5,600 3,344
OTHER INCOME, net 0 (37) (316)
OPERATING LOSS 2,963 8,273 3,238
FINANCIAL EXPENSES, net 27 140 2,681
SHARE IN NET INCOME OF ASSOCIATED COMPANY 0 0 (46)
LOSS BEFORE INCOME TAXES 2,990 8,413 5,873
TAX (INCOME) EXPENSES (83) 37 (396)
NET LOSS 2,907 8,450 5,477
NET INCOME (LOSS) ATTRIBUTABLE TO NON- CONTROLLING INTERESTS (INCLUDING REDEEMABLE) (163) (139) 134
NET LOSS ATTRIBUTABLE TO THE COMPANY $ 2,744 $ 8,311 $ 5,611
LOSS PER SHARE:      
Basic $ 0.19 $ 0.55 $ 0.52
Diluted $ 0.19 $ 0.55 $ 0.52
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE:      
Basic 15,423,040 15,571,568 10,775,877
Diluted 15,423,040 15,571,568 10,775,877
COMPREHENSIVE LOSS:      
Net loss $ 2,907 $ 8,450 $ 5,477
Other comprehensive (income) loss - translation adjustments (244) 484 (707)
Comprehensive loss 2,663 8,934 4,770
Comprehensive (income) loss attributed to non-controlling interests (including redeemable) (163) (139) 134
COMPREHENSIVE LOSS ATTRIBUTED TO ORGENESIS INC. $ 2,500 $ 8,795 $ 4,904